Evolus Inc. Common Stock (EOLS)
Stock · NASDAQ · Health Care
$8.89as of 8/28/2026
Price chart
Open in TradingViewActive signals
RSI Negative Divergence26.0%
High Beta22.3%
Support level
$4.29
Industry
Biotechnology: Pharmaceutical Preparations
About EOLS
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes vario…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 353
- Website
- www.evolus.com/
Fundamentals
- 1-day range
- $7.21$7.8
- Market cap
- $487.98M
- P/E (trailing)
- —
- P/E (forward)
- 29.42
- EPS (trailing)
- $-0.67
- Dividend yield
- —
- Beta
- 1.37
- Avg. volume
- 794.2K
52-week range
$3.86$9.12
Next earnings: November 4, 2026 · EPS estimate $-0.08confirmed
How Evolus Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 3, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Buy 85%
Hold 15%
Sell 0%
1-year price forecast
High
$20
+125.1%
Median
$14
+57.6%
Low
$10
+12.5%
Evolus Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- EOLSEvolus Inc. Common Stock$8.89▲ 0.06%Market cap $487.98MP/E —$3.86$9.12
- AQSTAquestive Therapeutics Inc. Common Stock$5.02▼ 2.71%Market cap $491.83MP/E —$2.93$7.55
- QTTBQ32 Bio Inc. Common Stock$15.01▼ 7.06%Market cap $482.18MP/E 15.71$1.62$23.57
- RZLTRezolute Inc. Common Stock (NV)$4.62▼ 7.23%Market cap $452.57MP/E —$1.07$11.46
- BNTCBenitec Biopharma Inc. Common Stock$12.51▼ 1.30%Market cap $451.07MP/E —$9.85$16.76
- PRTAProthena Corporation plc Ordinary Shares$9.35▲ 2.86%Market cap $449.19MP/E —$7.73$11.8
- LRMRLarimar Therapeutics Inc. Common Stock$4▼ 1.23%Market cap $436.31MP/E —$2.72$6.42
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| EOLS Evolus Inc. Common Stock | $487.98M | — | $8.89 | ▲ 0.06% | $3.86$9.12 |
| AQST Aquestive Therapeutics Inc. Common Stock | $491.83M | — | $5.02 | ▼ 2.71% | $2.93$7.55 |
| QTTB Q32 Bio Inc. Common Stock | $482.18M | 15.71 | $15.01 | ▼ 7.06% | $1.62$23.57 |
| RZLT Rezolute Inc. Common Stock (NV) | $452.57M | — | $4.62 | ▼ 7.23% | $1.07$11.46 |
| BNTC Benitec Biopharma Inc. Common Stock | $451.07M | — | $12.51 | ▼ 1.30% | $9.85$16.76 |
| PRTA Prothena Corporation plc Ordinary Shares | $449.19M | — | $9.35 | ▲ 2.86% | $7.73$11.8 |
| LRMR Larimar Therapeutics Inc. Common Stock | $436.31M | — | $4 | ▼ 1.23% | $2.72$6.42 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $13 Price Targetbenzinga · 8/25/2026
- HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $13 Price TargetBenzinga · 8/25/2026
- Following Heightened Competition from Botox, Xeomin, and Long-Acting Daxxify, New Study Evaluates Dysport (abobotulinumtoxinA) Revenue Trajectory Through 2034Yahoo · 8/17/2026
- Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to TradeYahoo · 8/11/2026
- Evolus: The Injectable Platform Is Becoming The Real MoatSeekingAlpha · 8/11/2026
- Evolus, Inc. 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha · 8/6/2026
- Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Surges 21% and Adjusted EBITDA ...Yahoo · 8/6/2026
- Evolus Q2 Earnings Call HighlightsYahoo · 8/6/2026
- Evolus (NASDAQ:EOLS) Tops Q2 EPS Estimates and Raises Revenue Guidance, Shares Gain 5.7%ChartMill · 8/6/2026
Insider Activity
Insider Actions →Acquired
76.3K
Disposed
163.5K
- MOATAZEDI DAVID · March 20, 2026 · Sale13.7K @ $4.75
- Avelar Rui · March 20, 2026 · Sale3.1K @ $4.75
- MOATAZEDI DAVID · March 17, 2026 · Sale116.7K @ $4.89
- Avelar Rui · March 17, 2026 · Sale30.0K @ $4.89
- MOATAZEDI DAVID · March 16, 2026 · Option Exercise67.5K
- Avelar Rui · March 16, 2026 · Option Exercise8.8K
Institutional Ownership
March 31, 2026
- Total shares held
- 45.58M
- Total value held
- $186.81M
- Institutional holders
- 143
Top holders this quarter
- Unknown6.38M
- Unknown4.29M
- Unknown3.11M
- Unknown2.63M
- Unknown2.47M
- Unknown2.25M
- Unknown2.18M
- Unknown1.46M
- Unknown1.40M
- Unknown1.38M
See the full, filterable feed with live charts on the MarketWall dashboard.